IM Cannabis Corp. (IMCC) stock

IMCCNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 30, 2026Score 4/30

$0.57+0.02 (+2.75%)

Close on Nov 13, 2026Market cap $3.35MP/E –Yield –

IM Cannabis price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

IM Cannabis's price to sales ratio was 0.2× on Nov 11, 2026, against 5.7× a year earlier. Over the last 5 years it ranged from 0.2× to 413.6×, with a median of 5.7×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.2×	−4.0
2025	Dec 31, 2025	4.3×	−0.3
2024	Dec 31, 2024	4.6×	+1.1
2023	Dec 29, 2023	3.5×	−4.6
2022	Dec 30, 2022	8.1×	−312.3
2021	Dec 31, 2021	320.4×	−18.9
2020	May 29, 2020	339.4×	–

Where these numbers come from

Parsed from the XBRL in IM Cannabis's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Aug 27, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IMCC.

Compare: IMCC vs CGC · IMCC vs CWLXF · IMCC vs CRON · IMCC vs ACB · IMCC vs LEEEF

Revenue growth1.3% · median 33.2%

Gross margin17.7% · median 35.5%

Operating margin-21.2% · median -25.4%

Net margin-20.7% · median -29.5%

Company	Revenue	Growth
CGC	C$308.32M	+10.7%
CRON	$206.20M	+55.8%
IMCC	C$54.73M	+1.3%
CWLXF	–	–
ACB	–	–
LEEEF	–	–

Company

Exchange: Nasdaq
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: December 31
Employees: 95
Auditor: KOST FORER GABBAY & KASIERER
SEC CIK: 1792030

Advertisement
300 × 250

See a number that looks wrong?